ELI LILLY AND COMPANY |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 30.87 CAD | +0.75% |
|
+1.65% | +40.06% |
| Sales 2024 * | 42.98B 58.56B 3,373B | Sales 2025 * | 52.62B 71.7B 4,130B | Capitalization | 739B 1,006B 57,973B |
|---|---|---|---|---|---|
| Net income 2024 * | 11.93B 16.26B 937B | Net income 2025 * | 16.55B 22.55B 1,299B | EV / Sales 2024 * | 17.6 x |
| Net Debt 2024 * | 18.07B 24.62B 1,418B | Net Debt 2025 * | 15B 20.43B 1,177B | EV / Sales 2025 * | 14.3 x |
| P/E ratio 2024 * |
61.4
x | P/E ratio 2025 * |
44.2
x | Employees | 43,000 |
| Yield 2024 * |
0.63% | Yield 2025 * |
0.73% | Free-Float | 99.8% |
More Fundamentals
* Assessed data
More news
Latest transcript on Eli Lilly and Company
More recommendations
More press releases
More news
| 1 day | +0.75% | ||
| 1 week | +1.65% | ||
| 1 month | +5.47% | ||
| 3 months | +4.57% | ||
| 6 months | +39.81% | ||
| Current year | +40.06% |
1 week
29.64
31.04
1 month
27.4731.04
Current year
21.8531.04
1 year
21.1731.04
3 years
21.1731.04
5 years
21.1731.04
10 years
21.1731.04
| Managers | Title | Age | Since |
|---|---|---|---|
David Ricks
CEO | Chief Executive Officer | 56 | 31/12/95 |
Anat Ashkenazi
DFI | Director of Finance/CFO | 51 | 31/12/00 |
Ruth Gimeno
PSD | President | - | - |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 63 | 24/01/21 | |
Ralph Alvarez
BRD | Director/Board Member | 68 | 31/03/09 |
Jon Fyrwald
BRD | Director/Board Member | 63 | 31/12/04 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 31/05/24 | 30.87 | +0.75% | 22,302 |
| 30/05/24 | 30.64 | +0.49% | 19,580 |
| 29/05/24 | 30.49 | +0.63% | 18,814 |
| 28/05/24 | 30.3 | -2.26% | 34,745 |
| 27/05/24 | 31 | +2.07% | 3,375 |
End-of-day quote NEO Exchange, May 30, 2024
More quotes
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
Pharmaceuticals
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
820.3
USD
Average target price
852.5
USD
Spread / Average Target
+3.92%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +32.83% | 598B | |
| -6.30% | 353B | |
| +15.15% | 318B | |
| +4.05% | 285B | |
| +15.00% | 240B | |
| +9.78% | 210B | |
| -5.52% | 206B | |
| +6.17% | 164B | |
| -0.45% | 162B |
- Stock Market
- Equities
- LLY Stock
- LLY Stock
